TAVI procedure volume poised to spike

29 August 2019 (Last Updated August 30th, 2019 09:25)

Transcatheter aortic valve implantation (TAVI) is a relatively new procedure for the minimally invasive replacement of a patient’s aortic valve. In recent years, TAVI has exploded as an extremely successful intervention, with a current market cap of $3B.

TAVI procedure volume poised to spike

According to GlobalData estimates, in recent years, Transcatheter aortic valve implantation (TAVI) has exploded as an extremely successful intervention, with a current market cap of $3B.

What is TAVI?

Transcatheter aortic valve implantation (TAVI) is a relatively new procedure for the minimally invasive replacement of a patient’s aortic valve. It is done while the heart is still beating, in contrast to the current gold standard in the industry, surgical heart valve replacement (SAVR). In SAVR, the heart is stopped so that the new valve can be implanted.

Due to the relatively recent advent of TAVI technology, it is less tested than its more established cousin SAVR. As such, while SAVR has been proven to be safe on all but the most infirm patients, TAVI has struggled to earn this clearance. The procedure has generally only been allowed to be performed on ‘high risk’ and ‘inoperable’ patients. These are individuals with severe complications or who are very physically weak and would not survive a SAVR procedure. It was originally introduced as a measure to save these patients, who would otherwise be treated as terminally ill.

TAVI’s growing popularity

Proponents of this technology have long been pushing for an expansion of its indications. They argue that it can also be an effective treatment for medium- to low-risk patients as well, due to the clinical benefits it could offer over SAVR.

With some recent clinical trials, the FDA has approved TAVI systems from Edwards LifeSciences and Medtronic for low-risk patients. This increase in use cases can result in up to 165,000 additional prospective patients per year across the world, and additional revenues of up to $4.9B dollars. To see whether TAVI can replace SAVR successfully, Edwards and Medtronic will continue to monitor the patients in their trial for the upcoming decade to determine the long-term viability of these devices.

Should TAVI prove to be a suitable replacement, we can expect to see double-digit growth over the coming years.